Optune Lua offers new hope for metastatic NSCLC patients
Novocure has received CE mark approval for Optune Lua, its wearable device designed to treat metastatic non-small cell lung cancer (NSCLC) using tumor-treating fields (TTFields) technology.
The system uses non-invasive, wearable arrays to apply physical forces on dividing cancer cells, disrupting tumor growth. Already FDA-approved, Optune Lua is the first treatment in over eight years to significantly extend survival in metastatic NSCLC without systemic toxicity.
Key Highlights:
- CE mark enables EU market entry, starting with Germany
- Based on positive Phase 3 LUNAR trial results
- Offers a non-toxic, innovative treatment alternative
“This milestone marks a major step in advancing care for patients with aggressive lung cancers,” said Frank Leonard, President of Novocure Oncology.
Follow MEDWIRE.AI for the latest breakthroughs in cancer treatment technologies.
